Antibiotic treatment of ophthalmic infection: new developments.
The introduction of quinolones has dramatically altered antibiotic therapy for serious ophthalmic infections. The newer cephalosporins are also playing a more significant role. The recently introduced macrolides, particularly azithromycin, have great potential for treating not only serious infections, but also some of the less serious ones. These new developments are discussed, and the cost implications of new antibiotic treatment on ophthalmology is described.
Andrews
V
V
Pharmacy Department, Moorfields Eye Hospital, London, UK.
D042462:4-Quinolones; D000900:Anti-Bacterial Agents / Q000191:economics / Q000627:therapeutic use*; D000890:Anti-Infective Agents / Q000191:economics / Q000627:therapeutic use*; D002511:Cephalosporins / Q000191:economics / Q000627:therapeutic use*; D016527:Drug Costs; D005128:Eye Diseases / Q000188:drug therapy*; D006801:Humans; D007239:Infections / Q000188:drug therapy*; D018942:Macrolides
D042462:4-Quinolones; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002511:Cephalosporins; D018942:Macrolides